EyePoint Named One of BioSpace's 2027 Best Places to Work
EyePoint Pharmaceuticals has been recognized as one of the top five small employers in the life sciences industry in BioSpace's 2027 Best Places to Work list.
Stocks · News reference
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
EyePoint Pharmaceuticals, Inc. announced its schedule for upcoming investor conferences and scientific meetings throughout November and December 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pomerantz LLP Investigates Potential Securities Fraud Claims Against EyePoint, Inc.
Pomerantz LLP has initiated an investigation into EyePoint, Inc. regarding potential securities fraud or unlawful business practices following recent clinical trial results.
EyePoint, Inc. to Report Third Quarter 2026 Financial Results on November 12, 2026
EyePoint, Inc. announced it will host a conference call and live webcast on November 12, 2026, to discuss its third quarter 2026 financial results and recent corporate developments.
JonesTrading Downgrades EyePoint Pharmaceuticals to Hold
JonesTrading analyst Debanjana Chatterjee has downgraded EyePoint Pharmaceuticals (NASDAQ: EYPT) from a previous rating to a Hold rating.
EyePoint Pharmaceuticals Announces Workforce Reduction and Termination of Pivotal Wet AMD Trials
EyePoint Pharmaceuticals is cutting its workforce by 50% and ending its late-stage clinical trials for wet age-related macular degeneration (AMD) following a second clinical trial failure.
Wall Street Analysts Downgrade EyePoint Pharmaceuticals Following Clinical Trial Results
Multiple financial institutions, including JPMorgan, Mizuho Securities, and Guggenheim, downgraded EyePoint Pharmaceuticals' stock rating following the company's recent clinical trial failure.